EagleClaw Capital Managment LLC Cuts Stock Holdings in Becton, Dickinson and Company $BDX

EagleClaw Capital Managment LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 29.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,671 shares of the medical instruments supplier’s stock after selling 9,445 shares during the period. EagleClaw Capital Managment LLC’s holdings in Becton, Dickinson and Company were worth $4,400,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 71.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after buying an additional 34,437 shares in the last quarter. Transcend Capital Advisors LLC increased its holdings in Becton, Dickinson and Company by 88.2% in the third quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock valued at $1,084,000 after buying an additional 2,715 shares in the last quarter. Assetmark Inc. increased its holdings in Becton, Dickinson and Company by 49.5% in the third quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock valued at $42,294,000 after buying an additional 74,795 shares in the last quarter. Finally, Belpointe Asset Management LLC purchased a new position in Becton, Dickinson and Company in the third quarter valued at about $650,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Up 0.8%

Shares of BDX opened at $148.36 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The firm has a 50 day simple moving average of $151.84 and a 200-day simple moving average of $177.23. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The stock has a market cap of $40.88 billion, a price-to-earnings ratio of 37.56, a price-to-earnings-growth ratio of 10.42 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same period last year, the company posted $3.35 EPS. The company’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Wall Street Analyst Weigh In

BDX has been the subject of a number of research analyst reports. Citigroup dropped their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Argus dropped their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday, March 23rd. Evercore increased their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Jefferies Financial Group dropped their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Finally, TD Cowen dropped their target price on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday, May 4th. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $183.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.